| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
2,6-Dimethoxybenzoic acid is a chemical intermediate and does not have a well-defined primary pharmacological target. It may be used as a precursor or building block for the synthesis of bioactive molecules. In some contexts, benzoic acid derivatives have been studied for antimicrobial or anti-inflammatory activities, but 2,6-dimethoxybenzoic acid itself is primarily a synthetic intermediate.
|
|---|---|
| ln Vitro |
As a synthetic intermediate, 2,6-dimethoxybenzoic acid does not have established in vitro biological activity. It may be used in assays to evaluate the activity of downstream synthetic products or as a negative control in structure-activity relationship studies. The compound's methoxy groups may influence its physicochemical properties and reactivity in synthetic transformations.
|
| ln Vivo |
There are no established in vivo activities for 2,6-dimethoxybenzoic acid as it is primarily used as a synthetic building block rather than a pharmacologically active compound. Its in vivo effects would be dependent on the specific derivatives or prodrugs synthesized from it.
|
| Enzyme Assay |
As a chemical intermediate, 2,6-dimethoxybenzoic acid is not typically used in receptor binding or enzyme assays. However, if used in such assays, the compound would be dissolved in an appropriate solvent (e.g., DMSO or ethanol) and tested at varying concentrations against the target of interest. Binding or inhibition would be measured using standard biochemical techniques (e.g., radioligand binding, fluorescence polarization, or enzymatic activity assays).
|
| Cell Assay |
2,6-Dimethoxybenzoic acid is not typically used in cell-based assays as a pharmacologically active compound. If used, cells would be treated with varying concentrations of the compound dissolved in culture medium (with DMSO content kept below 0.1–1% to avoid cytotoxicity). Cell viability, proliferation, or other endpoints would be assessed using standard assays (MTT, SRB, etc.).
|
| Animal Protocol |
As a synthetic intermediate, 2,6-Dimethoxybenzoic acid is not typically used in animal studies. If used, it would be administered via oral, intraperitoneal, or intravenous routes at appropriate doses. Pharmacokinetic parameters (absorption, distribution, metabolism, excretion) would be determined, and toxicological endpoints would be assessed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 2,6-dimethoxybenzoic acid would be typical of small, moderately lipophilic aromatic acids. It is expected to be well-absorbed orally, metabolized in the liver (likely via demethylation and conjugation), and excreted in urine. The compound has a molecular weight of 182.17 and is soluble in organic solvents but poorly soluble in water.
|
| Toxicity/Toxicokinetics |
2,6-Dimethoxybenzoic acid has low toxicity as a chemical intermediate. Standard safety precautions should be followed when handling the compound. It may cause skin, eye, and respiratory tract irritation. The compound is not intended for human use and is for research purposes only.
|
| Additional Infomation |
2,6-Dimethoxybenzoic acid belongs to the benzene family and is a carbonyl compound. It has been reported that 2,6-dimethoxybenzoic acid exists in carnations, curculigo, and ranunculus capitulata, and relevant data are available for reference.
2,6-Dimethoxybenzoic acid is a benzoic acid derivative used as a building block in organic synthesis and pharmaceutical research. It is a white to off-white crystalline solid with two methoxy substituents at the 2- and 6-positions. The compound is used in the synthesis of various bioactive molecules and natural product analogs. |
| Molecular Formula |
C9H10O4
|
|---|---|
| Molecular Weight |
182.1733
|
| Exact Mass |
182.057
|
| CAS # |
1466-76-8
|
| PubChem CID |
15109
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
314.5±22.0 °C at 760 mmHg
|
| Melting Point |
185187°C
|
| Flash Point |
126.5±15.8 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.533
|
| LogP |
0.98
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MBIZFBDREVRUHY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O4/c1-12-6-4-3-5-7(13-2)8(6)9(10)11/h3-5H,1-2H3,(H,10,11)
|
| Chemical Name |
2,6-dimethoxybenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~548.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
